J2357 HCPCS code: Injection, omalizumab, 5 mg
J2357 is the HCPCS Level II code for injection, omalizumab, 5 mg. In 2024 Medicare paid an average of $29.33 per service for J2357 across 7,268,072 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 120 per day on outpatient hospital claims. Medicare volume rose 8% from 2022 to 2024 (6,749,348 to 7,268,072 services). In 2024, about 4,582 clinicians billed Medicare for J2357 for 12,557 beneficiaries; Florida, Texas, California accounted for 30% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2005-01-01 |
| Last action effective | 2005-01-01 |
Who bills J2357 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 4,582 |
| Medicare beneficiaries | 12,557 |
| States with claims | 48 |
| Share of services in top 3 states (Florida, Texas, California) | 30% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J2357, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 6,749,348 | 12,031 | $36.76 | $29.24 |
| 2023 | 6,975,757 | 12,378 | $37.27 | $29.60 |
| 2024 | 7,268,072 | 12,557 | $36.95 | $29.33 |
States with the most J2357 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Florida | 874,695 | $29.75 |
| Texas | 674,636 | $29.36 |
| California | 597,806 | $28.60 |
| Virginia | 378,095 | $29.53 |
| Arizona | 350,415 | $29.74 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 120 | Prescribing Information |
| practitioner claims | 120 | Prescribing Information |
Medicare policy articles for this code
- A52448: Billing and Coding: Omalizumab and biosimilar, OMLYCLO® (omalizumab-igec) (Wellpoint Federal (MAC - Part A, MAC - Part B))
Covered diagnoses (17 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| J33.0 | Polyp of nasal cavity | 1 |
| J45.40 | Moderate persistent asthma, uncomplicated | 1 |
| J45.41 | Moderate persistent asthma with (acute) exacerbation | 1 |
| J45.42 | Moderate persistent asthma with status asthmaticus | 1 |
| J45.50 | Severe persistent asthma, uncomplicated | 1 |
| J45.51 | Severe persistent asthma with (acute) exacerbation | 1 |
| J45.52 | Severe persistent asthma with status asthmaticus | 1 |
| L50.1 | Idiopathic urticaria | 1 |
| L50.6 | Contact urticaria | 1 |
| L50.8 | Other urticaria | 1 |
Showing 10 of 17. The full list, non-covered diagnoses and CSV export are in Caduvo.
What changed for J2357
- 2005-01-01: J2357 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J2357?
J2357 is the HCPCS Level II code for injection, omalizumab, 5 mg. Short descriptor: "Omalizumab injection".
How much does Medicare pay for J2357?
In 2024, the average Medicare payment was $29.33 per service (average allowed $36.95).
Does Medicare cover J2357?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Which diagnoses support coverage for J2357?
Medicare policy articles that cite J2357 list 17 covered ICD-10-CM diagnosis codes across 1 article. The most cited include J33.0 (Polyp of nasal cavity), J45.40 (Moderate persistent asthma, uncomplicated), J45.41 (Moderate persistent asthma with (acute) exacerbation). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of J2357 can be billed per day?
120 on outpatient hospital claims; 120 on practitioner claims (NCCI medically unlikely edits).
Related J23 codes
- J2300 — Injection, nalbuphine hydrochloride, per 10 mg
- J2305 — Injection, nitroglycerin, 5 mg
- J2310 — Injection, naloxone hydrochloride, per 1 mg
- J2311 — Injection, naloxone hydrochloride (zimhi), 1 mg
- J2312 — Injection, naloxone hydrochloride, not otherwise specified, 0.01 mg
- J2313 — Injection, naloxone hydrochloride (zimhi), 0.01 mg
- J2315 — Injection, naltrexone, depot form, 1 mg
- J2320 — Injection, nandrolone decanoate, up to 50 mg
- J2323 — Injection, natalizumab, 1 mg
- J2325 — Injection, nesiritide, 0.1 mg
- J2326 — Injection, nusinersen, 0.1 mg
- J2327 — Injection, risankizumab-rzaa, intravenous, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J2357
- Watch J2357 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J2357
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.